Medical Condition News

RSS

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

IsoRay, Inc., announced today that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer.

21 Jan 2010

MDRNA to receive European patent for its intranasal insulin formulation

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the European Patent Office intends to grant a patent for application EP06826368 covering formulations for the intranasal delivery of rapid acting insulin, and its use for the treatment of diabetes.

21 Jan 2010

CPRIT awards the first $61M in grants for cancer research

The Cancer Prevention and Research Institute of Texas (CPRIT) awarded on January 20th the first $61 million in grants for cancer research projects at academic institutions and private companies throughout Texas. These are the inaugural grants of the $3 billion to be invested in cancer research in Texas over the next ten years.

21 Jan 2010

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Amgen today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix® (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME '203' and '181' trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010.

21 Jan 2010

Genomic Health announces global commercial availability of its Oncotype DX colon cancer test

Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.

21 Jan 2010

China Pharma Holdings announces completion of clinical trials for Candesartan

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that the Company has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production application to the SFDA.

21 Jan 2010

Neuralstem announces treatment of first ALS patient with spinal cord stem cells

Neuralstem, Inc. announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA. A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.

21 Jan 2010

Enrollment complete in Vertos Medical's U.S. IRB I "mild" procedure Patient Outcomes Trial

Medical device company Vertos Medical Inc. has announced the completion of enrollment in its post-market U.S. IRB (Institutional Review Board) I Patient Outcomes Trial, a 75-patient study of the mild procedure. The open-label, single-arm, prospective, IRB-approved study is intended to gather patient outcomes data following treatment for symptomatic central canal spinal stenosis using proprietary mild devices. Results from the trial, which is being conducted by 14 investigators at academic and private practice settings across the United States, are expected to be published during 2010.

21 Jan 2010

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

BioNumerik Pharmaceuticals, Inc. today announced the treatment of the first patients in a global multi-center Phase III clinical trial of Tavocept (BNP7787) in patients with primary adenocarcinoma of the lung, the most common type of lung cancer. In previous studies, Tavocept demonstrated the potential to substantially increase overall and one year patient survival while concurrently preventing and reducing the incidence and severity of common chemotherapy side-effects as compared to other currently available treatments for advanced lung cancer.

21 Jan 2010

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

Pfizer Inc. and Auxilium Pharmaceuticals, Inc. today announced that Pfizer received notification from the European Medicines Agency that the Marketing Authorization Application (MAA) for XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, biologic for the treatment of Dupuytren’s contracture (a condition resulting in the contracture of the fingers into the palm), has completed the validation phase successfully. As a result, the scientific/technical review procedure commenced on 21 January 2010.

21 Jan 2010

Osteoporosis-related event of 2010 to be held in Florence, Italy

Don't miss the most important osteoporosis-related event of 2010, to be held in the center of Florence, Italy from May 5 to 8, 2010.

21 Jan 2010

Christiana Care Health System earns Gold Seal of Approval for Primary Stroke Centers

Christiana Care Health System has earned the Gold Seal of Approval(TM) from The Joint Commission for Primary Stroke Centers. Christiana Care earned this distinction after the Joint Commission conducted an on-site review in November 2009.

21 Jan 2010

Efficacy of neurofeedback in treating ADD/ADHD

On January 22, the Potomac Institute for Policy Studies will present a guest lecture by Don DuRousseau, founder and CEO of Human Bionics LLC, a neurotechnology company specializing in brain-computer interface (BCI) systems. Mr. DuRousseau will explore the use of neurotechnology techniques, including the increasingly popular neurofeedback, as a treatment for ADD/ADHD.

21 Jan 2010

Results of two pivotal Phase III clinical trials with oral FTY720 published

Results of the TRANSFORMS and FREEDOMS studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine, providing comprehensive evidence to support the efficacy and safety profile of this first-in-class therapy for multiple sclerosis (MS).

21 Jan 2010

Natural grass/cleat combination lowers strain and less likely to cause ACL injury

Athletes put less strain on their anterior cruciate ligament (ACL) while making a cut on a natural grass surface while wearing a cleat.

21 Jan 2010

Phase 3 clinical trial results of Inspire Pharmaceuticals' PROLACRIA announced

Inspire Pharmaceuticals, Inc. announced today that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA™ (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet its primary endpoint (p = 0.526) or its secondary endpoint (p = 0.368).

21 Jan 2010

Moxifloxacin more favorable than amoxicillin/clavulanate for COPD exacerbations

Chronic obstructive pulmonary disease (COPD) affects a large number of subjects worldwide and is characterised by a progressively rising epidemiological, clinical and socio-economic impact. The objectives of treatment are to decrease the burden of the disease through relief of symptoms, improvement of exercise tolerance, and prevention and treatment of exacerbations.

21 Jan 2010

Ontario must stay the course in the fight against lung cancer

Currently an estimated 7,800 Ontarians are diagnosed with lung cancer and approximately 6,000 die of the disease each year. Smoking and exposure to second-hand smoke continue to be the main risk factors for developing lung cancer - and that is why we must continue to encourage Ontarians to be smoke-free.

21 Jan 2010

Special report on A-Fib to be premiered in RLTV's Healthline series

Retirement Living TV's (RLTV) award-winning series, Healthline will premiere a special report on Atrial Fibrillation. This half-hour episode explores the possible symptoms, risk factors and treatments to successfully live with this chronic illness.

21 Jan 2010

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

In a significant step toward restoring healthy blood circulation to treat a variety of diseases, a team of scientists at Weill Cornell Medical College has developed a new technique and described a novel mechanism for turning human embryonic and pluripotent stem cells into plentiful, functional endothelial cells, which are critical to the formation of blood vessels.

21 Jan 2010

Medical Condition News

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

MDRNA to receive European patent for its intranasal insulin formulation

CPRIT awards the first $61M in grants for cancer research

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Genomic Health announces global commercial availability of its Oncotype DX colon cancer test

China Pharma Holdings announces completion of clinical trials for Candesartan

Neuralstem announces treatment of first ALS patient with spinal cord stem cells

Enrollment complete in Vertos Medical's U.S. IRB I "mild" procedure Patient Outcomes Trial

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

Osteoporosis-related event of 2010 to be held in Florence, Italy

Christiana Care Health System earns Gold Seal of Approval for Primary Stroke Centers

Efficacy of neurofeedback in treating ADD/ADHD

Results of two pivotal Phase III clinical trials with oral FTY720 published

Natural grass/cleat combination lowers strain and less likely to cause ACL injury

Phase 3 clinical trial results of Inspire Pharmaceuticals' PROLACRIA announced

Moxifloxacin more favorable than amoxicillin/clavulanate for COPD exacerbations

Ontario must stay the course in the fight against lung cancer

Special report on A-Fib to be premiered in RLTV's Healthline series

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News